Article Sidebar

Submitted
February 11, 2025
Accepted
June 1, 2025
Published
June 30, 2025
Download
PDF
Statistic
Read Counter : 24

Main Article Content

Abstract

Traditional cancer therapies are often limited by nonspecific distribution, leading to systemic toxicity and poor therapeutic outcomes. Targeted drug delivery systems aim to overcome these limitations by directing therapeutic agents specifically to tumor tissues, minimizing off-target effects. Recent advances have introduced sophisticated platforms, including nanoparticles, liposomes, dendrimers, micelles, and antibody-drug conjugates (ADCs). This review explores the design principles of these delivery systems, their mechanisms of targeting (passive via the enhanced permeability and retention effect and active via ligand-receptor interactions), and their clinical applications. Challenges such as drug resistance, immunogenicity, and tumor heterogeneity are also discussed. Future directions include stimuli-responsive systems, personalized nanomedicine, and combination therapies integrating immunotherapy and targeted delivery.

Keywords

Drug delivery systems nanoparticles targeted therapy cancer treatment pharmacology

Article Details

How to Cite
1.
Ghadah Ali Al-Oudah, Thamer Mahmood N, Fouad Mohammed D. Recent Progress in Targeted Drug Delivery Systems for Cancer Treatment. JBB [Internet]. 2025 Jun. 30 [cited 2025 Sep. 28];4(2):75-97. Available from: http://biomedbiochem.nabea.pub/biomedbiochem/article/view/96
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

How to Cite

1.
Ghadah Ali Al-Oudah, Thamer Mahmood N, Fouad Mohammed D. Recent Progress in Targeted Drug Delivery Systems for Cancer Treatment. JBB [Internet]. 2025 Jun. 30 [cited 2025 Sep. 28];4(2):75-97. Available from: http://biomedbiochem.nabea.pub/biomedbiochem/article/view/96
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the definition of cancer. Molecular Cancer Research. 2023 Nov 1;21(11):1142-7. Doi: https://doi.org/10.1158/1541-7786.MCR-23-0411.
  2. Anand U, Dey A, Chandel AK, Sanyal R, Mishra A, Pandey DK, De Falco V, Upadhyay A, Kandimalla R, Chaudhary A, Dhanjal JK. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & diseases. 2023 Jul 1;10(4):1367-401. 10.1016/j.gendis.2022.02.007
  3. Morales-Cruz M, Delgado Y, Castillo B, Figueroa CM, Molina AM, Torres A, Milián M, Griebenow K. Smart targeting to improve cancer therapeutics. Drug design, development and therapy. 2019 Oct 30:3753-72. Doi:https://doi.org/10.2147/DDDT.S219489
  4. Li J, Wang Q, Xia G, Adilijiang N, Li Y, Hou Z, Fan Z, Li J. Recent advances in targeted drug delivery strategy for enhancing oncotherapy. Pharmaceutics. 2023 Aug 29;15(9):2233. Doi:https://doi.org/10.3390/pharmaceutics15092233
  5. Kreuzinger C, Geroldinger A, Smeets D, Braicu EI, Sehouli J, Koller J, Wolf A, Darb-Esfahani S, Joehrens K, Vergote I, Vanderstichele A. A complex network of tumor microenvironment in human high-grade serous ovarian cancer. Clinical Cancer Research. 2017 Dec 15;23(24):7621-32. Doi:https://doi.org/10.1158/1078-0432.CCR-17-1159.
  6. Yu H, Ning N, Meng X, Chittasupho C, Jiang L, Zhao Y. Sequential drug delivery in targeted cancer therapy. Pharmaceutics. 2022 Mar 5;14(3):573. Doi:https://doi.org/10.3390/pharmaceutics14030573
  7. Sanchez-Moreno P, Ortega-Vinuesa JL, Peula-Garcia JM, Marchal JA, Boulaiz H. Smart drug-delivery systems for cancer nanotherapy. Current drug targets. 2018 Mar 1;19(4):339-59. Doi:https://doi.org/10.2174/1389450117666160527142544
  8. Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Research. 2002 Jun;4:1-5. Doi:https://doi.org/10.1186/bcr432
  9. Allahou LW, Madani SY, Seifalian A. Investigating the application of liposomes as drug delivery systems for the diagnosis and treatment of cancer. International journal of biomaterials. 2021;2021(1):3041969. Doi:https://doi.org/10.1155/2021/3041969
  10. Kim EG, Kim KM. Strategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeutics. Biomolecules & therapeutics. 2015 Nov 1;23(6):493. Doi:https://doi.org/10.4062/biomolther.2015.116
  11. Peters C, Brown S. Antibody–drug conjugates as novel anti-cancer chemotherapeutics. Bioscience reports. 2015 Jul 14;35(4):e00225. Doi:https://doi.org/10.1042/BSR20150089
  12. Hanafy NA, El-Kemary M, Leporatti S. Micelles structure development as a strategy to improve smart cancer therapy. Cancers. 2018 Jul 20;10(7):238. Doi:https://doi.org/10.3390/cancers10070238
  13. Zhang Y, Sun C. Current status, challenges and prospects of antifouling materials for oncology applications. Frontiers in Oncology. 2024 May 8;14:1391293. Doi:https://doi.org/10.3389/fonc.2024.1391293
  14. Yoon DJ, Liu CT, Quinlan DS, Nafisi PM, Kamei DT. Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer. Annals of biomedical engineering. 2011 Apr;39:1235-51. Doi:https://10.1007/s10439-011-0280-y
  15. Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers. 2019 May 8;11(5):640. Doi:https://10.3390/cancers11050640.
  16. Lim EK, Jang E, Lee K, Haam S, Huh YM. Delivery of cancer therapeutics using nanotechnology. Pharmaceutics. 2013 May 15;5(2):294-317. Doi:https://10.3390/pharmaceutics5020294
  17. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nature communications. 2018 Apr 12;9(1):1410. Doi:https://doi.org/10.1038/s41467-018-03705-y
  18. Zhang Y, Zheng X, Huang Y, Li S, Li X, Zhu L. EDB-FN-targeted probes for near infrared fluorescent imaging and positron emission tomography imaging of breast cancer in mice. Scientific Reports. 2024 Sep 27;14(1):22056. Doi:https://doi.org/10.1038/s41598-024-73362-3
  19. Gupta C, Jaipuria A, Gupta N. Inhalable formulations to treat non-small cell lung cancer (NSCLC): Recent therapies and developments. Pharmaceutics. 2022 Dec 31;15(1):139. Doi:https:// doi.org/10.3390/pharmaceutics15010139
  20. Durfee PN. Synthesis, characterization, and application of monosized mesoporous silica nanoparticle-supported lipid bilayers for targeted therapeutic delivery to individual cells (Doctoral dissertation, The University of New Mexico). Doi:https://doi.org/10.1021/acsnano.6b02819. Epub 2016 Jul 25
  21. Balzer AH, Whitehurst CB. An analysis of the biotin–(strept) avidin system in immunoassays: Interference and mitigation strategies. Current Issues in Molecular Biology. 2023 Oct 31;45(11):8733-54. Doi:https://doi.org/10.3390/cimb45110549.
  22. Parveen S, Gupta P, Kumar S, Banerjee M. Lipid polymer hybrid nanoparticles as potent vehicles for drug delivery in cancer therapeutics. Medicine in Drug Discovery. 2023 Dec 1;20:100165. Doi:https://doi.org/10.1016/j.medidd.2023.100165
  23. Korsmeyer R. Critical questions in development of targeted nanoparticle therapeutics. Regenerative Biomaterials. 2016 Jun 1;3(2):143-7. Doi:https://doi.org/10.1093/rb/rbw011.
  24. Lang X, Wang X, Han M, Guo Y. Nanoparticle-mediated synergistic chemoimmunotherapy for cancer treatment. International Journal of Nanomedicine. 2024 Dec 31:4533-68. Doi:https://doi.org/10.2147/IJN.S455213
  25. Huang R, Zhu J, Fan R, Tang Y, Hu L, Lee H, Chen S. Extracellular vesicle-based drug delivery systems in cancer. Extracellular Vesicle. 2024 Dec 1;4:100053. Doi:https://doi.org/10.1016/j.vesic.2024.100053

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.